Navigating the Complexities of Molecularly Driven Therapy in Follicular Lymphoma

This chapter delves into the complexities of molecularly driven therapies for follicular lymphoma, highlighting the struggle of having targets without effective drugs. The discussion also examines the mixed efficacy of BCL-2 inhibitors and the need for personalized treatment approaches amid standardized algorithms.